--- title: "Black Diamond Therapeutics (BDTX) news: offering" url: "https://aibio.space/companies/black-diamond-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BDTX offering news: Black Diamond Therapeutics files $500,000,000 replacement shelf with $150,000,000 ATM. Black Diamond Therapeutics, Inc." --- BDTX Black Diamond Therapeutics, Inc. NASDAQ · United States # Black Diamond Therapeutics (BDTX) news BDTX offering news Financings · 2025-11-13 ## [Black Diamond Therapeutics files $500,000,000 replacement shelf with $150,000,000 ATM](https://aibio.space/news/black-diamond-therapeutics-files-500-000-000-replacement-shelf-150-000/) The new shelf replaces one that expires on November 22, 2025. It carries forward $400,005,680.55 of securities that remain unsold under the earlier registration. ## Latest Black Diamond Therapeutics news We have not published a story on Black Diamond Therapeutics yet. When there is news, it will appear here. ## Black Diamond Therapeutics at a glance - **Ticker**: BDTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $110.5 million ### Related companies - [Sionna Therapeutics](https://aibio.space/companies/sionna-therapeutics/) NASDAQ: SION - [Kymera Therapeutics](https://aibio.space/companies/kymera-therapeutics/) NASDAQ: KYMR - [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) NASDAQ: SANA - [Cartesian Therapeutics](https://aibio.space/companies/cartesian-therapeutics/) NASDAQ: RNAC - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) NASDAQ: CNXU - [NeoImmuneTech](https://aibio.space/companies/neoimmunetech/) KRX: 950220 - [Instil Bio](https://aibio.space/companies/instil-bio/) NASDAQ: TIL - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) NASDAQ: RLAY ### Also on NASDAQ - [BIOHARVEST SCIENCES INC.](https://aibio.space/companies/bioharvest-sciences/) BHST - [Lyell Immunopharma](https://aibio.space/companies/lyell-immunopharma/) LYEL - [Ascendis Pharma](https://aibio.space/companies/ascendis-pharma/) ASND - [Nuwellis](https://aibio.space/companies/nuwellis/) NUWE - [Tarsus Pharmaceuticals](https://aibio.space/companies/tarsus-pharmaceuticals/) TARS - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) AGIO ## What Black Diamond Therapeutics does Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies, which target families of oncogenic mutations that share a similar protein structure and selectivity profile. The company aims to treat genetically defined tumors, overcome resistance, minimize toxicity mediated by wild-type protein and reach central nervous system disease. Its lead program is silevertinib, formerly BDTX-1535, a brain-penetrant, fourth-generation EGFR MasterKey inhibitor. Silevertinib is in a Phase 2 trial in patients with EGFR mutant non-small cell lung cancer in both the frontline and recurrent settings, and the company plans a randomized Phase 2 trial in newly diagnosed patients with EGFR altered glioblastoma in the second quarter of 2026. The FDA granted silevertinib Fast Track designation for EGFR mutant C797S-positive non-small cell lung cancer whose disease progressed on or after a third-generation EGFR TKI. The pipeline also includes an outlicensed clinical-stage product candidate and one development-stage candidate. The company works with Guardant Health on real-world evidence for patients with non-classical EGFR mutations. | Product or program | What it is | Stage | |---|---|---| | Silevertinib (formerly BDTX-1535) | Brain-penetrant fourth-generation EGFR MasterKey inhibitor for lung cancer and glioblastoma | Phase 2 in EGFR mutant NSCLC; Fast Track designation | Summarised from the company's [10-K filed Mar 16, 2026](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm). ## Black Diamond Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$33.6 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/) | [$51.3 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/) | | Net income (loss) | [$22.4 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/) | [-$69.7 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/) | | Cash from operations | [$29.6 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/) | [-$62.3 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/) | | Cash and equivalents | [$21.0 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000025/) | [$36.4 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/) | | Short-term investments | [$107.7 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000025/) | [$62.1 million](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $19.2 million, plus short-term investments of $91.3 million, $110.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Black Diamond Therapeutics Has Black Diamond Therapeutics raised money recently? Our latest story on this, dated Nov 13, 2025: "Black Diamond Therapeutics files $500,000,000 replacement shelf with $150,000,000 ATM". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/black-diamond-therapeutics-files-500-000-000-replacement-shelf-150-000/). What is the ticker symbol of Black Diamond Therapeutics? Black Diamond Therapeutics, Inc. trades under the ticker BDTX on NASDAQ. Where is Black Diamond Therapeutics listed? Black Diamond Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Black Diamond Therapeutics? The SEC Central Index Key (CIK) for Black Diamond Therapeutics, Inc. is 1701541. Its filings are on SEC EDGAR. How many shares does Black Diamond Therapeutics have outstanding? 57,453,747 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Black Diamond Therapeutics listed under? Our directory records Black Diamond Therapeutics, Inc. under United States. What does Black Diamond Therapeutics do? Our directory classifies Black Diamond Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Black Diamond Therapeutics? The ISIN recorded for Black Diamond Therapeutics, Inc. is US09203E1055. Does aibio.space cover Black Diamond Therapeutics? aibio.space lists Black Diamond Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does Black Diamond Therapeutics develop? Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies, which target families of oncogenic mutations that share a similar protein structure and selectivity profile. The company aims to treat genetically defined tumors, overcome resistance, minimize toxicity mediated by wild-type protein and reach central nervous system disease. What is Silevertinib (formerly BDTX-1535) from Black Diamond Therapeutics? Silevertinib (formerly BDTX-1535): Brain-penetrant fourth-generation EGFR MasterKey inhibitor for lung cancer and glioblastoma Stage: Phase 2 in EGFR mutant NSCLC; Fast Track designation. Is Black Diamond Therapeutics profitable? Black Diamond Therapeutics, Inc. reported net income of $22.4 million for the fiscal year ended Dec 31, 2025, and generated $29.6 million of cash from operations, per its annual report to the SEC. How much does Black Diamond Therapeutics spend on research and development? $33.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Black Diamond Therapeutics have? $110.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Black Diamond Therapeutics (BDTX) stock news? Our latest story on Black Diamond Therapeutics, dated Nov 13, 2025: "Black Diamond Therapeutics files $500,000,000 replacement shelf with $150,000,000 ATM". The new shelf replaces one that expires on November 22, 2025. It carries forward $400,005,680.55 of securities that remain unsold under the earlier registration. [Source](https://aibio.space/news/black-diamond-therapeutics-files-500-000-000-replacement-shelf-150-000/). ## Investor discussion: Black Diamond Therapeutics Members talk about Black Diamond Therapeutics (BDTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Black Diamond Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-11-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1701541/000110465925111490/tm2531084-1_s3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BDTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-BDTX/). ## SEC filings and registration - **SEC name**: Black Diamond Therapeutics, Inc. - **CIK**: 1701541 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: BDTX (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142 - **Phone**: 617-417-5868 - **Shares outstanding**: 57,453,747 as of 2026-07-30 (10-Q filed 2026-08-05) - **Former names**: Aset Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000025/bdtx-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/bdtx-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1701541/000110465926078847/tm2619324d1_8k.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1701541/000110465926065254/tm2615293d1_8k.htm) filed 2026-05-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000017/bdtx-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000015/bdtx-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1701541/000110465926051474/tm261476-3_def14a.htm) filed 2026-04-29 - [10-K](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm) filed 2026-03-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001701541), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Black Diamond Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BDTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Black Diamond Therapeutics, Inc. - **Ticker**: BDTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US09203E1055 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BDTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/black-diamond-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Black Diamond Therapeutics (BDTX) news: offering", 2026-10-31, https://aibio.space/companies/black-diamond-therapeutics/